Published in BMJ on June 01, 2002
Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med (2009) 6.89
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ (2005) 2.80
The double-edged sword of COX-2 selective NSAIDs. CMAJ (2002) 2.57
Why we need easy access to all data from all clinical trials and how to accomplish it. Trials (2011) 2.25
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res (2007) 1.57
Efficacy and safety of COX 2 inhibitors. BMJ (2002) 1.57
Principles for evidence-based drug formulary policy. J Gen Intern Med (2005) 1.22
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut (2003) 1.20
Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology (2009) 1.19
The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. J Anesth (2006) 1.11
Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol (2013) 1.10
Why don't we initiate more large simple randomized controlled trials? CMAJ (2003) 1.08
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis (2004) 1.06
Failures of the therapeutic chain as a cause of drug ineffectiveness. BMJ (2003) 1.05
Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond. Br J Clin Pharmacol (2004) 1.03
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer (2006) 1.03
Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska. Health Serv Res (2008) 1.00
The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol (2006) 0.95
Complicity theory: an explanation for the 'coxib problem'? J R Soc Med (2006) 0.92
Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res (2012) 0.91
Non-surgical treatment of osteoarthritis: a half century of "advances". Ann Rheum Dis (2004) 0.90
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol (2003) 0.90
Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists. Eur J Clin Pharmacol (2003) 0.88
COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed (2004) 0.88
Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. Eur J Clin Pharmacol (2003) 0.85
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther (2005) 0.85
Potential alternatives to COX 2 inhibitors. BMJ (2002) 0.85
Building a better aspirin: gaseous solutions to a century-old problem. Br J Pharmacol (2007) 0.85
Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 0.84
Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J (2004) 0.84
Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr (2008) 0.83
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev (2013) 0.82
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. Arthritis Res Ther (2002) 0.82
Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br J Clin Pharmacol (2009) 0.82
Activation of peripheral KCNQ channels attenuates inflammatory pain. Mol Pain (2014) 0.81
cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci (2010) 0.81
Selective COX-2 inhibitors: a health economic perspective. Wien Med Wochenschr (2003) 0.81
An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol (2007) 0.81
Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect? J R Soc Med (2006) 0.81
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated. BMJ (2003) 0.81
Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol (2007) 0.78
Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. Eur J Clin Pharmacol (2004) 0.78
Analgesia for patients with advanced disease: 2. Postgrad Med J (2004) 0.78
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity. BMJ (2003) 0.77
Commonality of defensive roles of COX-2 in the lung and gut. Am J Pathol (2006) 0.77
ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials. Ann Intern Med (2016) 0.77
New dogmas or old? Gut (2003) 0.76
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial. BMJ (2002) 0.76
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib? BMJ (2005) 0.75
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. BMJ (2002) 0.75
Drug company sues Spanish bulletin over fraud claim. BMJ (2004) 0.75
[Treatment of osteoarthritis with COX-2 inhibitors: good for the stomach, but bad for the patient?]. Ugeskr Laeger (2002) 0.75
Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study. Cost Eff Resour Alloc (2006) 0.75
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis. BMJ (2002) 0.75
NSAIDs. BMJ Clin Evid (2010) 0.75
US Food and Drug Administration gets it right. BMJ (2002) 0.75
Stability of diclofenac sodium oral suspensions packaged in amber polyvinyl chloride bottles. Can J Hosp Pharm (2010) 0.75
The ethics of changing practice: do we cross the line? J Extra Corpor Technol (2009) 0.75
Are selective COX 2 inhibitors superior to traditional NSAIDs? Little is known about COX 2 inhibitors. BMJ (2002) 0.75
Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations. Open Access Rheumatol (2011) 0.75
Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains. PLoS One (2014) 0.75
NSAIDs. BMJ Clin Evid (2007) 0.75
Unbalanced reporting of benefits and harms in abstracts on rofecoxib. Eur J Clin Pharmacol (2010) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA (2001) 3.28
Researchers deny any attempt to mislead the public over JAMA article on arthritis drug. BMJ (2001) 2.94
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA (2001) 2.42
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol (2003) 16.17
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med (2011) 15.02
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol (2005) 10.56
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 9.88
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med (2004) 6.87
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med (2007) 6.17
Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ (2010) 5.68
Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med (2012) 4.87
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med (2014) 4.37
Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol (2006) 3.78
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
Quality of reporting of randomized trials as a measure of methodologic quality. JAMA (2002) 3.60
All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ (2011) 3.51
Lessons from the withdrawal of rofecoxib. BMJ (2004) 3.33
Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum (2007) 3.22
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16
Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med (2005) 3.08
Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ (2007) 2.93
Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ (2010) 2.88
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87
Transcutaneous electrostimulation for osteoarthritis of the knee. Cochrane Database Syst Rev (2009) 2.65
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation (2009) 2.47
The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ (2009) 2.29
Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med (2013) 2.25
Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med (2014) 2.24
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation (2012) 2.17
Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol (2010) 2.16
Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. Circulation (2013) 2.13
A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol (2009) 2.13
Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev (2015) 2.11
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
Predictors of outcomes of total knee replacement surgery. Rheumatology (Oxford) (2012) 2.05
An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J (2011) 1.98
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention (2009) 1.94
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol (2011) 1.86
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84
Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv (2012) 1.84
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.81
An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J (2009) 1.79
Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum (2007) 1.76
Quality of reporting of diagnostic accuracy studies. Radiology (2005) 1.70
Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J (2013) 1.70
2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) (2015) 1.69
Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. Circulation (2011) 1.64
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol (2007) 1.54
Diagnostic value of sonography in patients with suspected carpal tunnel syndrome: a prospective study. Arthritis Rheum (2005) 1.54
Prevalence of cam-type deformity on hip magnetic resonance imaging in young males: a cross-sectional study. Arthritis Care Res (Hoboken) (2010) 1.53
Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. Eur Heart J (2012) 1.52
A systematic review finds that diagnostic reviews fail to incorporate quality despite available tools. J Clin Epidemiol (2005) 1.51
Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev (2009) 1.51
Uses and misuses of the STROBE statement: bibliographic study. BMJ Open (2011) 1.50
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. JACC Cardiovasc Interv (2012) 1.49
Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J (2012) 1.47
Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol (2012) 1.44
Matched-pair study showed higher quality of placebo-controlled trials in Western phytotherapy than conventional medicine. J Clin Epidemiol (2007) 1.44
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. Ann Intern Med (2014) 1.42
Sirolimus versus paclitaxel coronary stents in clinical practice. Catheter Cardiovasc Interv (2011) 1.41
Ranking of tests for pain hypersensitivity according to their discriminative ability in chronic neck pain. Reg Anesth Pain Med (2013) 1.40
Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J (2012) 1.33
Systolic blood pressure below 110 mmHg is associated with increased mortality in penetrating major trauma patients: Multicentre cohort study. Resuscitation (2011) 1.31
Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis (2012) 1.31
The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum (2009) 1.30
Allocation concealment in clinical trials. JAMA (2002) 1.28
Variation of a test's sensitivity and specificity with disease prevalence. CMAJ (2013) 1.27
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ (2012) 1.20
Therapeutic ultrasound for osteoarthritis of the knee or hip. Cochrane Database Syst Rev (2010) 1.17
A systematic review classifies sources of bias and variation in diagnostic test accuracy studies. J Clin Epidemiol (2013) 1.17
Variation in age and physical status prior to total knee and hip replacement surgery: a comparison of centers in Australia and Europe. Arthritis Rheum (2009) 1.16
Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention (2012) 1.15
Factor analysis of responses to thermal, electrical, and mechanical painful stimuli supports the importance of multi-modal pain assessment. Pain (2011) 1.15
Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation (2012) 1.12
Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. Am Heart J (2011) 1.12
Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med (2006) 1.10